Thursday, February 7, 2019
1:00 p.m. – 2:00 p.m. ET
The U.S. capital markets remain an attractive source of capital for emerging companies in the life sciences sector. Over 21.7% of the 2017 IPOs were life sciences companies. Many of these IPOs were preceded by late stage (or mezzanine) private placements made principally to U.S. institutional investors.
- Financing alternatives for pre-IPO companies;
- The late-stage (or “cross-over”) private placement market;
- Considering milestones when planning a financing strategy; and
- Post-IPO alternatives, including registered direct offerings, PIPE transactions, at the market offerings, and related financing considerations
To register, please click here.